American Diversified
Holdings Corporation (USOTC: ADHC) Formally enters $200 Billion
Cannabis Industry by forming Operating Business: American Cannabis
Holdings, Inc.
ADHC Files Current
Year End Financials Valuing AURACIStm
Migraine
Bio-Device Patents In
Excess of
$500,000.
DEL MAR, CA.
-- October 16, 2018 -- InvestorsHub NewsWire -- American
Diversified Holdings Corporation (USOTC:
ADHC) has filed its current year end financials which can be
found under the ticker symbol ADHC at
www.otcmarkets.com
After closely
following the Cannabis markets ADHC management has determined the
timing is appropriate for entering this sector and has formed an
operating business which will be the vehicle for managing business
initiatives. The company will be offering a selection of life style
products in the legal cannabis market as our first initiatives in
the Cannabis sector.
The impetus to fully
enter the Cannabis space is based upon several events have
occurred; including full legalization in Canada on October
17th,
Relaxation of federal rules on CBD, Major investments by
multi-national beverage companies in the infused beverage arena and
numerous analyst reports indicating the US Cannabis market to grow
to over $200 billion in the next decade.
American Cannabis
Holdings Inc. will be initially focused on Direct to Consumer
markets primarilyin
infused
beverages, Medical Cannabis and will continue to monitor the US
federal policy for additional market opportunities.
Management is in late
stage negotiations with Cannabis industry partners and will be
updating shareholders in the near term.
In additional news
ADHC has filed its' current year end financials. Brazos Biomedical,
Inc. and its patented technology AURACIStm
migraine
management device are
progressing along its
development path.
"The
Auracis
international patent
portfolio includes two issued US patents and international
counterparts. The patent portfolio covers the head-worn,
electrode-containing device to be used for pain from migraine
headaches," commented ADHC management.
ADHC recently filed
financials value the patent portfolio in excess of $500,000. Recent
reports indicate that the US migraine surpasses $55 billion in
treating over 38 million people suffering from
migraines.
The
AURACIStm
TENS
(transcutaneous electric nerve stimulation) migraine device was
derived from the OMEGA surgical procedure, where electrodes are
implanted in the cranium under the skin blocking nerve impulses.
Management believes a less invasive non-surgical non-opioid head
worn TENS device will provide relief for the millions of patients
that do not qualify for a surgical procedure or are looking for an
alternative to traditional medications.
Investors can find a
complete overview of all the AURACIS information on the
www.BrazosBiomedical.com website.
ADHC is a holding
company that provides executive management, corporate governance,
administrative support, financial advice, and introductions to
capital sources to various micro-cap private and public companies
that have proven revenues and business models.
BRAZOS BIOMEDICAL LLC
is a bio device company utilizing electro stimulation for pain
management to improve patient outcomes through creative innovation
with a core competency in the migraine and headache pain
space.
This press release
contains forward-looking statements pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These statements include risks and uncertainties that may cause the
Company's plans to change and are in no way intended to guarantee
that the Company will be successful in executing its plans. common
stock currently trades on the over-the-counter under the symbol
ADHC. This press release in no way constitutes any recommendation
regarding the securities of ADHC or its affiliates. Any person
reading this press release is advised that this release should be
considered in the light of all facts and circumstances regarding
the business and financial condition and prospects of ADHC, and no
reference has been made that this release contains all
information.
Contact:
adhcinvestor@gmail.com
Tel:
858-259-4534